Equities researchers at Westpark Capital assumed coverage on shares of Veru (NASDAQ:VERU – Get Free Report) in a research note issued on Tuesday, Marketbeat.com reports. The firm set a “buy” rating on the stock.
Other equities research analysts also recently issued reports about the company. Weiss Ratings raised Veru from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Wall Street Zen downgraded Veru from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.
Veru Trading Down 3.1%
Veru (NASDAQ:VERU – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. Equities analysts predict that Veru will post -1.07 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of VERU. Royal Bank of Canada boosted its holdings in shares of Veru by 69.3% in the 1st quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after acquiring an additional 5,008 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Veru in the 1st quarter worth approximately $153,000. Finally, FNY Investment Advisers LLC acquired a new position in shares of Veru in the 2nd quarter worth approximately $328,000. 47.16% of the stock is owned by institutional investors and hedge funds.
About Veru
Veru Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity, oncology and related conditions. The company’s research programs are designed to address cancer-related muscle loss and treatment challenges, as well as the loss of lean muscle that can accompany significant weight reduction.
Veru’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function.
Further Reading
- Five stocks we like better than Veru
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.
